Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced its new five-year strategy, "Alnylam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback